Disclaimer: This site aggregates publicly available data from official government sources (FDA, ClinicalTrials.gov, PubMed, SEC EDGAR) for general reference only. It does NOT constitute medical advice, diagnosis, treatment recommendations, or investment advice.

Clinical Trial

Tricuspid Regurgitation Treatment With LAPLACE Transcatheter Tricuspid Valve Replacement System

NCT: NCT07687485 · NOT_YET_RECRUITING

NCT IDNCT07687485
StatusNOT_YET_RECRUITING
Start Date2026-09
Completion2038-09
SponsorLaplace Interventional, Inc (INDUSTRY)
First posted
Last updated

Brief Summary

The objective of this clinical study is to assess the safety and efficacy of the Laplace Transcatheter Tricuspid Valve Replacement (TTVR) System for the treatment of symptomatic subjects with at least severe tricuspid regurgitation (TR).

Frequently Asked Questions

What is Tricuspid Regurgitation Treatment With LAPLACE Transcatheter Tricuspid Valve Replacement System?

Tricuspid Regurgitation Treatment With LAPLACE Transcatheter Tricuspid Valve Replacement System is a clinical trial registered under NCT07687485. Current status: NOT_YET_RECRUITING.

What is the status of NCT07687485?

The current status of NCT07687485 (Tricuspid Regurgitation Treatment With LAPLACE Transcatheter Tricuspid Valve Replacement System) is: NOT_YET_RECRUITING.

When did Tricuspid Regurgitation Treatment With LAPLACE Transcatheter Tricuspid Valve Replacement System start?

Tricuspid Regurgitation Treatment With LAPLACE Transcatheter Tricuspid Valve Replacement System started on 2026-09.

Official Source

View on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov API. For the most current status, refer to the official record.

↑